- Home
- GLDG vs ADCT Comparison
GLDG vs ADCT Comparison
Compare GLDG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDG
- ADCT
- Stock Information
- Founded
- GLDG 2009
- ADCT 2011
- Country
- GLDG Canada
- ADCT Switzerland
- Employees
- GLDG N/A
- ADCT N/A
- Industry
- GLDG Precious Metals
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GLDG Basic Materials
- ADCT Health Care
- Exchange
- GLDG Nasdaq
- ADCT Nasdaq
- Market Cap
- GLDG 317.0M
- ADCT 380.2M
- IPO Year
- GLDG N/A
- ADCT 2020
- Fundamental
- Price
- GLDG $1.41
- ADCT $4.07
- Analyst Decision
- GLDG Strong Buy
- ADCT Strong Buy
- Analyst Count
- GLDG 2
- ADCT 6
- Target Price
- GLDG $3.50
- ADCT $7.60
- AVG Volume (30 Days)
- GLDG 4.4M
- ADCT 1.2M
- Earning Date
- GLDG 10-10-2025
- ADCT 11-07-2025
- Dividend Yield
- GLDG N/A
- ADCT N/A
- EPS Growth
- GLDG N/A
- ADCT N/A
- EPS
- GLDG N/A
- ADCT N/A
- Revenue
- GLDG N/A
- ADCT $77,246,000.00
- Revenue This Year
- GLDG N/A
- ADCT $13.47
- Revenue Next Year
- GLDG N/A
- ADCT $5.88
- P/E Ratio
- GLDG N/A
- ADCT N/A
- Revenue Growth
- GLDG N/A
- ADCT 15.73
- 52 Week Low
- GLDG $0.71
- ADCT $1.05
- 52 Week High
- GLDG $1.80
- ADCT $4.74
- Technical
- Relative Strength Index (RSI)
- GLDG 49.85
- ADCT 52.04
- Support Level
- GLDG $1.38
- ADCT $3.92
- Resistance Level
- GLDG $1.71
- ADCT $4.31
- Average True Range (ATR)
- GLDG 0.13
- ADCT 0.29
- MACD
- GLDG -0.03
- ADCT -0.06
- Stochastic Oscillator
- GLDG 27.10
- ADCT 17.85
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).